Achaogen (AKAO) Downgraded by Mizuho to “Neutral”

Mizuho cut shares of Achaogen (NASDAQ:AKAO) from a buy rating to a neutral rating in a report issued on Friday, MarketBeat Ratings reports.

Several other research firms have also issued reports on AKAO. Stifel Nicolaus lifted their price target on shares of Achaogen from $14.00 to $22.00 and gave the stock a buy rating in a research report on Tuesday, August 7th. BidaskClub lowered shares of Achaogen from a sell rating to a strong sell rating in a research report on Wednesday, July 18th. Zacks Investment Research upgraded shares of Achaogen from a hold rating to a buy rating and set a $4.75 price target on the stock in a research report on Wednesday, October 10th. Needham & Company LLC lowered shares of Achaogen from a buy rating to a hold rating in a research report on Tuesday, August 7th. Finally, SunTrust Banks decreased their price target on shares of Achaogen from $16.00 to $10.00 and set a buy rating on the stock in a research report on Monday, August 20th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $14.81.

Achaogen stock traded down $0.40 during mid-day trading on Friday, hitting $2.25. The company’s stock had a trading volume of 1,656,391 shares, compared to its average volume of 579,029. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.79 and a current ratio of 3.79. The firm has a market cap of $139.24 million, a price-to-earnings ratio of -0.71 and a beta of 0.67. Achaogen has a twelve month low of $2.10 and a twelve month high of $15.00.

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. grew its position in Achaogen by 2.1% during the 1st quarter. BlackRock Inc. now owns 2,898,459 shares of the biopharmaceutical company’s stock worth $37,536,000 after purchasing an additional 60,613 shares in the last quarter. Granahan Investment Management Inc. MA purchased a new position in Achaogen during the 2nd quarter worth approximately $1,220,000. Teton Advisors Inc. grew its position in Achaogen by 324.2% during the 2nd quarter. Teton Advisors Inc. now owns 140,000 shares of the biopharmaceutical company’s stock worth $1,212,000 after purchasing an additional 107,000 shares in the last quarter. Gabelli Funds LLC grew its position in Achaogen by 18.6% during the 2nd quarter. Gabelli Funds LLC now owns 206,400 shares of the biopharmaceutical company’s stock worth $1,787,000 after purchasing an additional 32,400 shares in the last quarter. Finally, Gamco Investors INC. ET AL grew its position in Achaogen by 43.1% during the 2nd quarter. Gamco Investors INC. ET AL now owns 94,700 shares of the biopharmaceutical company’s stock worth $820,000 after purchasing an additional 28,500 shares in the last quarter. Hedge funds and other institutional investors own 60.17% of the company’s stock.

Achaogen Company Profile

Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Featured Article: What is a balanced fund?

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply